As advised via PHARMAC Tender Results of 30 August 2019 there is to be a change in the listing and future sole supply of Chloramphenicol.

New listing from 1 December 2019

Chloramphenicol-Deva Eye Oint 1% 5 gm OP                                         Pharmacode TBA                Schedule price $1.55

Incumbent brand

Chlorsig Eye Oint 1% 4 gm OP                                                                     Pharmacode 335150          Schedule price $2.48

HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 May 2020.

Brand switch fee not advised in Tender notification.

As of the date of this notification ProPharma / PWR cannot accept Chlorsig Eye Oint 1% for credit under any circumstances.

From 1 December 2019 community pharmacies dispensing Chloramphenicol Eye Oint 1% 4 gm will need to support patients changing to the new brand and manage stock during the transition.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.


Benefit of staying with incumbent while stock remains available are minimal, but every cent counts:-

Chlorsig : – Dispensing 1 OP. Therefore 1 @ $2.48 x 3% = $0.0744 plus  $0.256 (pack fee) giving you $0.3304

Chloramphenicol : – Dispensing 1 OP. Therefore 1 @ $1.55 x 3% = $0.0465 plus  $0.256 (pack fee) giving you $0.3025

You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 May 2020. Failure to do so may prove very costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 May 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author